Search

everythinglearnresearchcommunity

for

Search:↓

The user is experiencing a strange hair loss pattern despite using dutasteride for 3 years and minoxidil with tretinoin for 1.5 years. They recently added microneedling and are considering a scalp biopsy to understand the cause.

CB-03-01 is a topical anti-androgen with low absorption, offering potential as a side-effect-free alternative to Finasteride/Dutasteride for hair loss. It's in stage 2 clinical trials for acne and showing promise for male pattern baldness.

The user "baselinesims" shared their progress in treating hair loss using 1mg oral finasteride, 1ml topical minoxidil, 0.5ml topical dutasteride, keto shampoo, cosmerna, and micro needling. They are happy with the progress so far, with diffuse thinning being taken care of and baby hairs showing up. They plan on getting a hair transplant in the future. Other users commented on the improved appearance and mentioned that the lighting in the photos may affect the comparison.

Corticosterone inhibits GAS6, affecting hair follicle stem-cell activity, with potential implications for stress-related hair loss. Ashwagandha and Vitamin K are suggested for reducing cortisol, but their effectiveness is debated.

The conversation is about creating a topical hair loss treatment with B6, zinc, and azelaic acid, which is claimed to inhibit 90% of scalp DHT. One user is skeptical about the effectiveness of this treatment and its comparison to other treatments without side effects.

Chris's hair transplant looks better, but the hairline is criticized for being too straight and unnatural. Some recommend using finasteride and minoxidil for maintenance.

Hopeful treatments for hair loss, including Verteporfin, Androgen Receptor Degradation, and SCUBE3. These treatments offer potential solutions to slow or stop the effects of androgens on the scalp.

Hair follicle stem cells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.

Triple Hair Inc. developed a new topical treatment, TH07, combining Finasteride, Latanoprost, and Minoxidil for androgenic alopecia. Users discussed its effectiveness compared to other treatments and shared their own product combinations.

The user is seeking advice for the best topical treatment to combat their ongoing hair loss, despite already using oral dutasteride, RU-58841, and minoxidil. They are considering adding CB-03-01 or topical Spiro to their regimen to lower testosterone levels at the follicles.

A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.

Hair follicles are mostly dormant but can be reactivated with treatments like minoxidil, finasteride, and microneedling. A new drug, PP405, shows promise for hair regrowth but may not be available until 2027-2028.

The user asks about the order and compatibility of using topical minoxidil, stemoxydine, The Ordinary natural moisturizing factors + HA for scalp, RU58841, and Nioxin system 2 leave-in treatment. They seek advice on layering these hair loss treatments.

The user is experiencing diffuse androgenic alopecia and is trying various treatments, including 5mg finasteride, loniten, and Formula 82D, which contains dutasteride, a steroid, and tretinoin. They report potential regrowth with Formula 82D, despite previous treatments being ineffective.

Using a combination of low-dose topical finasteride (0.025%) and 0.5% pyrilutamide for hair loss, with a focus on minimizing side effects. The user seeks experiences and results from others who have tried this combination.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

Some embrace baldness, while others promote treatments like minoxidil and finasteride. Opinions differ on accepting baldness versus pursuing hair regrowth.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.

The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

A 25-year-old with AGA experienced hair thinning and dandruff, stabilized with topical finasteride and minoxidil but saw minimal regrowth. They seek advice on styling and consider oral minoxidil and microneedling for denser hair.

A 23-year-old is experiencing hair that is thick at the ends but thin at the roots despite using minoxidil and finasteride for 10 months. They are concerned about whether this is normal or a sign of miniaturization and seek advice on reversing or improving the condition.

TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.

Minoxidil and finasteride can help regrow hair, especially in thinning areas, but restoring completely receded temples is challenging and may require a hair transplant. Some users report success with these treatments, particularly when combined with microneedling.

Adding non-prescription topicals like alfatradiol and Zix to a standard fin/min/niz regimen may help with scalp inflammation and shedding, but their long-term effectiveness varies. Zix is recommended for reducing scalp inflammation and enhancing the effectiveness of other treatments.

The conversation discusses hair transplants, including the use of techniques like FUE and the importance of a good donor area to avoid visible bald patches. It also touches on alternative treatments like Minoxidil, Finasteride, and Pyrolutimide, and debates the idea of embracing baldness versus seeking treatments.

The conversation discusses hair loss linked to BDNF-increasing nootropics like Semax and Lions Mane. Suggested topical treatments include capsaicin, beta-glucan, and ginseng to counteract TGF-B activation.